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Introduction
In newborns, there are various etiologies for papule,
papule-vesiculae, pustulae or bullae skin lesions. Among
infectious causes, viral infection such as congenital
herpes simplex virus (HSV) carries the highest mor-
tality if acyclovir treatment is not adequate; group B
Streptococcus constitutes the most common perinatal
bacterial infection. However, some noninfectious tran-
sient conditions, such as erythema toxicum neonato-
rum, require no medication. It is mandatory to obtain
an accurate diagnosis for persistent skin lesions in new-
borns in order to prevent life-threatening conse-
quences. Here, we report the case of a 1-month-old
baby girl with vesiculopapular skin lesions who was 
otherwise well, who had poor response to acyclovir ini-
tially. Skin biopsy finally proved neonatal Langerhans
cell histiocytosis (LCH).
Case Report
The baby girl was born by Cesarean section at 38 weeks
of gestation to a healthy mother, with a birth body
weight of 3,039 g. At the age of 10 days, she began to
show generalized skin lesions, which were initially
papules, followed by central vesicles, which finally
became crateriform after crust formation. The mother
did not pay much attention to them because the baby
was otherwise well. At the age of 1 month, she was
brought to a well-baby clinic for a routine check and
vaccination. Admission was suggested under the
impression of congenital herpes simplex infection.
Tracing her family history, neither of her parents had
any sexually-transmitted diseases or skin lesions sug-
gesting herpes simplex infection.
On admission, the girl was alert and thriving, with
a body weight of 4,430 g. The vital signs were normal,
breathing sounds were clear, heart rate was regular,
and a neurological examination was normal. There was
no fever, hepatomegaly or lymphadenopathy. The skin
lesions, scattered over the scalp, face, oral mucosa, 4
extremities, trunk and buttocks, were crateriform
papulovesicular with crust in the center (Figure 1).
Blood test showed hemoglobin level of 11.7 g/dL,
white blood cell count of 12,600/μL, neutrophilic
segments, lymphocytes and monocytes of 35%, 57%
and 8% respectively, platelet count of 970 × 103/μL,
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and C-reactive protein < 0.1 mg/dL. Lumbar punc-
ture and brain sonography revealed no abnormalities.
Viral antigens and cultures were all negative except for
the antigen of type 1 HSV, which was positive.
Initially, she received intravenous acyclovir (10 mg/
kg/dose, q8h). However, the eruption of papulovesic-
ular lesions continued, so acyclovir was discontinued
and a skin biopsy was performed. Microscopically, the
epidermis showed focal spongiosis with eosinophil exo-
cytosis. In addition, loosely aggregated large cells, some
of which showed infolded/vesicular nuclei, were seen
in the epidermis and papillary dermis. A small amount
of mitosis was also noted. These large cells were weakly
positive for S-100 protein and strongly positive for
CD1a (Figure 2). In the upper dermis, there was mild
perivascular infiltration of inflammatory cells composed
of eosinophils and lymphohistiocytosis.
Tzanck smear showed no inclusion bodies.
Diagnosis of LCH was confirmed, and a systematic
survey was done. Routine skull radiography revealed
an osteolytic lesion in the left parietal area (Figure 3),
and chest X-ray showed mild reticulonodular infiltra-
tion. Abdominal sonography and biochemical tests
including erythrocyte sedimentation rate, prothrom-
bin time/activated partial thromboplastin time, fibrino-
gen, transferrin, total protein, alkaline phosphatase and
lactate dehydrogenase were normal.
Chemotherapy was suggested, but the family took
the baby to a second hospital where a diagnosis of
LCH was reconfirmed. She was initially treated with a
low-risk group regimen according to the guidelines of
the Taiwan Pediatric Oncology Group 2003 for LCH,
with prednisolone and vincristine for the first course.
The regimen was shifted to vincristine and methotrex-
ate (MTX) plus prednisolone (high risk group) due to
lung involvement. The skin lesions regressed after the
second course of chemotherapy.
The patient is now 16 months old, with a body
weight of 8.6kg and body length of 76cm. The whole
course of chemotherapy was completed, with no active
lesions remaining.
Discussion
Neonatal skin lesions are a common problem for both
parents and physicians. The etiology ranges from a
transient benign nature to serious underlying disease.
A health care provider should be aware of abnormal
lesions and provide adequate and timely intervention
to prevent devastating consequences. In this female
infant with vesiculopapular lesions, both infectious
and noninfectious causes were considered. Infectious
Figure 1. Crateriform papule-like vesicles with center crust on the
face of the infant.
Figure 2. Skin biopsy positive for CD1a: predominant stain in
membrane and weak cytoplasmic reactivity.
Figure 3. Osteolytic lesions on the left parietal bone of the skull.
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causes include HSV, varicella, cytomegalovirus, group
A or group B Streptococcus, Staphylococcus aureus,
Listeria, Pseudomonas and Candida albicans. Non-
infectious causes include erythema toxicum neonato-
rum, transient pustular melanosis, eosinophilic
pustular folliculitis and, rarely, LCH, epidermolysis
bullosa as well as congenital leukemia. Due to the
high mortality rate of most of the infectious causes of
neonatal skin lesions, we provided both antibiotics
and acyclovir before the infectious causes were elimi-
nated. In newborns, HSV infection carries a high
mortality rate: without antiviral therapy, the mortality
rate is 80%1 and with therapy, it is nearly 30%.2
In bacterial infections, group B Streptococcus and 
S. aureus are the most common pathogens; the for-
mer may lead to bacteremia, meningitis and pneumo-
nia and the latter, called impetigo neonatorum, may
cause osteomyelitis, pneumonia, sepsis and staphylo-
coccal scalded skin syndrome. Therefore, in new-
borns, it is necessary to start early therapy even in the
absence of a definite confirmation of the causative
organism. In this well-appearing infant, bacterial sep-
sis was unlikely, and HSV could be ruled out because
the virus cultures, PCR as well as Tzanck smear, were
negative, and the response to acyclovir treatment was
poor. Finally, skin biopsy revealed dermal infiltration
of histiocytes that were positive for CD1a and S-100
stain. Thus, a diagnosis of LCH was made.
The histiocyte group, the monocyte-macrophage
system of bone marrow origin, contains monocytes,
macrophages and dendritic cells, which serve as antigen-
presenting cells. LCH is a clonal proliferative disorder
of Langerhans cells. It constitutes a dysregulated im-
mune response with unsuccessful transition from
“innate” to “adaptive”, which leads to a lack of plasma
cells at the lesion site.3 The first presentation of LCH
was made by Paul Langerhans under an electron micro-
scope. The characteristic picture is Birbeck granules,
which are present in the cytoplasm and look like 
tennis rackets.4
In the past, LCH had the eponymous nomencla-
ture of histiocytosis X due to its unclear pathogenesis.
The histiocytic disorders are divided into 3 different
groups: (1) dendritic cell histiocytosis (to which LCH
belongs); (2) erythrophagocytic macrophage disor-
ders; and (3) malignant histiocytosis. Although the
disease mechanism is an abnormal proliferation of
cells, in the absence of aneuploidy, metaphase or karyo-
types, it is hard to define LCH as a neoplastic disor-
der. Also, the prognosis is diverse, ranging from
excellent survival without organ involvement to mul-
tiple organ infiltration requiring chemotherapy; self-
limiting disease has also been reported.
LCH can occur at any age; children below 15
years of age have a higher incidence rate of 8.9 per-
sons per million,5 and neonates below 28 days of age
1–2 persons per million.6 In Taiwan, the incidence
during 1995–1999 was 1.37–3.29 per million chil-
dren per year.7 The clinical presentation is single-organ
or multiorgan invasion of the skin, bone, lymphatic
system, liver, spleen, lungs and central nervous sys-
tem. Skin manifestations are often the first lesions to
be recognized.8 During the neonatal stage, such as in
our case, it usually presents as erythematous pustular
vesicles with crateriform ulceration and scaling, which
often leads to the misdiagnosis of congenital infectious
disease. At older ages, lesions are scaly and seborrhea-
like in the groin or scalp area.9
Hashimoto et al10 described a congenital self-healing
reticulohistiocytosis (Hashimoto-Pritzker disease) with
cutaneous lesions, mostly in the neonate stage. How-
ever, many studies have discovered that, though re-
ferred to as self-healing, some cases have multiorgan
invasion in the initial diagnosis while others have
relapse or multiorgan involvement later in life.11 A ret-
rospective study conducted by Stein et al11 found that
among 19 infants who had cutaneous eruptions before
the postnatal age of 4 weeks and who were diagnosed
with LCH later, 7 patients had skin lesions only, while
the other 12 patients had multiorgan involvement, of
whom 2 died. Greenberger et al12 found that children
younger than 2 years of age and with multiorgan
involvement had a higher mortality rate. Thus, com-
prehensive evaluation of all children with cutaneous
LCH is mandatory.
Treatment is not based on the subtype of LCH.
Instead, it depends on the organs involved. According
to the guidelines of the Taiwan Pediatric Oncology
Group 2003, LCH is divided into high-risk and low-
risk groups, for which the treatments are different. The
low-risk group is defined as patients older than 2 years
without liver, bone marrow or lung involvement.
Patients with multiorgan involvement and dysfunction
of the liver, lungs or bone marrow are enrolled in the
high-risk group. The localized cutaneous lesions can be
treated with steroids or short-term nitrogen mustard or
psoralen plus ultraviolet A therapy. Surgical resection
can be performed for localized cutaneous nodules or
single solitary bone lesions.
Chemotherapy for the low-risk group starts with
prednisolone (40 mg/m2/day) and vincristine
(1.5 mg/m2/dose, intravenous, weekly for 4 doses)
for 6 weeks followed by continuation therapy of pred-
nisolone (40mg/m2/day 5 days tri-weekly), vincristine
(1.5 mg/m2/dose tri-weekly) and 6-mercaptopurine
(50 mg/m2/day) for a total of 52 weeks of treatment.
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In the high-risk group, the initial therapy is composed
of MTX (500 mg/m2 biweekly for 2 doses), pred-
nisolone (40 mg/m2/day) and vincristine (1.5 mg/
m2/dose weekly for 4 doses) lasting for 6 weeks, fol-
lowed by MTX (20 mg/m2 weekly) with the same
regimen of continuation therapy as in the low-risk
group for 52 weeks of therapy. In this protocol, MTX
is regarded as the effective drug to maintain disease-
free status. Prognosis depends on the organs
involved, dysfunction of the organs and the response
to the chemotherapy.13
In Taiwan, Chen et al7 pointed out that local treat-
ment and disseminated LCH contributes to a high risk
of LCH aggressiveness. Patients who died initially pre-
sented with multisystem involvement and organ dys-
function including fever, anemia and thrombocytopenia,
which progressed to pancytopenia, refractory skin
involvement, massive hepatosplenomegaly and multior-
gan failure leading to death.
In conclusion, the skin manifestation of neonatal
LCH is always papulovesicular eruptions that mimic
other infectious diseases. It is not over-treatment to
give antibiotics or antiviral agents initially before the
condition has been proved to be a noninfectious dis-
ease. For unusual or persistent skin lesions, skin
biopsy with histopathologic and immunohistochemi-
cal studies are required to confirm the etiology. This
case report demonstrates the importance of skin biop-
sies, which can shorten the course to reach an accu-
rate diagnosis and provide timely intervention in such
cases. It is prudent to bear in mind the diagnosis of
congenital self-limiting LCH (Hashimoto-Pritzker
disease) in newborns. An intensive systematic survey
of the organs involved is required. Even if the child
only has cutaneous lesions, long-term surveillance is
indicated because it is possible to relapse or for multi-
organ involvement to occur later.
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